George F Murphy

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2089677/publications.pdf

Version: 2024-02-01

77	4,043	218677	123424
papers	citations	26 h-index	61 g-index

80	80	80	8109
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Allogeneic ABCB5+ Mesenchymal Stem Cells for Treatment-Refractory Chronic Venous Ulcers: A Phase I/IIa Clinical Trial. JID Innovations, 2022, 2, 100067.	2.4	12
2	T cell-attracting CCL18 chemokine is a dominant rejection signal during limb transplantation. Cell Reports Medicine, 2022, 3, 100559.	6.5	7
3	The Spatial Landscape of Progression and Immunoediting in Primary Melanoma at Single-Cell Resolution. Cancer Discovery, 2022, 12, 1518-1541.	9.4	87
4	Pathologies of oral and sinonasal mucosa following facial vascularized composite allotransplantation. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2021, 74, 1562-1571.	1.0	13
5	Ex vivo-expanded highly pure ABCB5+ mesenchymal stromal cells as Good Manufacturing Practice-compliant autologous advanced therapy medicinal product for clinical use: process validation and first in-human data. Cytotherapy, 2021, 23, 165-175.	0.7	26
6	ATF-3 expression inhibits melanoma growth by downregulating ERK and AKT pathways. Laboratory Investigation, 2021, 101, 636-647.	3.7	8
7	COVID-19 and graft-versus-host disease: a tale of two diseases (and why age matters). Laboratory Investigation, 2021, 101, 274-279.	3.7	5
8	Digital dermatopathology: The time is now. Journal of Cutaneous Pathology, 2021, 48, 469-471.	1.3	8
9	Full facial retransplantation in a female patientâ€"Technical, immunologic, and clinical considerations. American Journal of Transplantation, 2021, 21, 3472-3480.	4.7	21
10	Abstract 2609: Hypoxia-mediated downregulation of GCNT2/I-antigen in metastatic melanoma accelerates disease progression and mortality. , 2021, , .		0
11	Assessing the Prognostic Significance of Tumor-Infiltrating Lymphocytes in Patients With Melanoma Using Pathologic Features Identified by Natural Language Processing. JAMA Network Open, 2021, 4, e2126337.	5.9	23
12	Loss of the Epigenetic Mark 5-hmC in Psoriasis: Implications for Epidermal Stem Cell Dysregulation. Journal of Investigative Dermatology, 2020, 140, 1266-1275.e3.	0.7	16
13	Mucosa and Rejection in Facial Vascularized Composite Allotransplantation: A Systematic Review. Transplantation, 2020, 104, 2616-2624.	1.0	29
14	Accelerated chronic skin changes without allograft vasculopathy: A 10-year outcome report after face transplantation. Surgery, 2020, 167, 991-998.	1.9	23
15	Paraneoplastic Hypomyopathic Dermatomyositis Associated With EGFR Exon-20 Insertion NSCLC. Journal of Thoracic Oncology, 2019, 14, e128-e130.	1.1	5
16	In vivo safety profile and biodistribution of GMP-manufactured human skin-derived ABCB5-positive mesenchymal stromal cells for use in clinical trials. Cytotherapy, 2019, 21, 546-560.	0.7	35
17	Reversal of TET-mediated 5-hmC loss in hypoxic fibroblasts by ascorbic acid. Laboratory Investigation, 2019, 99, 1193-1202.	3.7	7
18	Differential distribution of the epigenetic marker 5â€hydroxymethylcytosine occurs in hair follicle stem cells during bulge activation. Journal of Cutaneous Pathology, 2019, 46, 327-334.	1.3	4

#	Article	IF	Citations
19	Chronic rejection of human face allografts. American Journal of Transplantation, 2019, 19, 1168-1177.	4.7	48
20	Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade. Cell, 2018, 173, 624-633.e8.	28.9	113
21	Epigenetic Reprogramming Strategies to Reverse Global Loss of 5-Hydroxymethylcytosine, a Prognostic Factor for Poor Survival in High-grade Serous Ovarian Cancer. Clinical Cancer Research, 2018, 24, 1389-1401.	7.0	43
22	Association of Nodal Metastasis and Mortality With Vermilion vs Cutaneous Lip Location in Cutaneous Squamous Cell Carcinoma of the Lip. JAMA Dermatology, 2018, 154, 701.	4.1	26
23	Biological significance of 5-hydroxymethylcytosine in oral epithelial dysplasia and oral squamous cell carcinoma. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2018, 125, 59-73.e2.	0.4	12
24	Increased levels of circulating MMP3 correlate with severe rejection in face transplantation. Scientific Reports, 2018, 8, 14915.	3.3	21
25	Nrf2 regulates CD4+ T cellâ€“induced acute graft-versus-host disease in mice. Blood, 2018, 132, 2763-2774.	1.4	26
26	Glucose-regulated phosphorylation of TET2 by AMPK reveals a pathway linking diabetes to cancer. Nature, 2018, 559, 637-641.	27.8	327
27	Loss of GCNT2/I-branched glycans enhances melanoma growth and survival. Nature Communications, 2018, 9, 3368.	12.8	40
28	Targeting antigen-presenting cells by antiâ€“PD-1 nanoparticles augments antitumor immunity. JCI Insight, 2018, 3, .	5.0	48
29	IL-1R Type 1â€“Deficient Mice Demonstrate an Impaired Host Immune Response against Cutaneous Vaccinia Virus Infection. Journal of Immunology, 2017, 198, 4341-4351.	0.8	12
30	Gene expression profiling of anti-CTLA4-treated metastatic melanoma in patients with treatment-induced autoimmunity. Laboratory Investigation, 2017, 97, 207-216.	3.7	13
31	5â€Hydroxymethylcytosine is a nuclear biomarker to assess biological potential in histologically ambiguous heavily pigmented melanocytic neoplasms. Journal of Cutaneous Pathology, 2017, 44, 249-255.	1.3	14
32	Targeting melanoma with front-line therapy does not abrogate Nodal-expressing tumor cells. Laboratory Investigation, 2017, 97, 176-186.	3.7	14
33	Toward an Objective Diagnostic Test for Bacterial Cellulitis. PLoS ONE, 2016, 11, e0162947.	2.5	16
34	ABCB5-Targeted Chemoresistance Reversal Inhibits Merkel Cell Carcinoma Growth. Journal of Investigative Dermatology, 2016, 136, 838-846.	0.7	19
35	Histopathologic spectrum of hypersensitivity reactions associated with anti-CD52 therapy (alemtuzumab). Journal of Cutaneous Pathology, 2016, 43, 989-993.	1.3	10
36	Increased GVHD-related mortality with broad-spectrum antibiotic use after allogeneic hematopoietic stem cell transplantation in human patients and mice. Science Translational Medicine, 2016, 8, 339ra71.	12.4	404

#	Article	IF	Citations
37	Failure of antibiotics in cellulitis trials: a systematic review and meta-analysis. American Journal of Emergency Medicine, 2016, 34, 1645-1652.	1.6	16
38	TET2 Negatively Regulates Nestin Expression in Human Melanoma. American Journal of Pathology, 2016, 186, 1427-1434.	3.8	6
39	Cutaneous Squamous Cell Carcinomas of the Lower Extremities Show Distinct Clinical and Pathologic Features. International Journal of Surgical Pathology, 2016, 24, 29-36.	0.8	9
40	ABCB5 Identifies Immunoregulatory Dermal Cells. Cell Reports, 2015, 12, 1564-1574.	6.4	51
41	Diagnostic Immunohistochemistry in Cutaneous Neoplasia: An Update. Dermatopathology (Basel,) Tj ETQq1 1 0.784314 rgBT /Overlo	1.5	68
42	Epigenetic markers in melanoma. Melanoma Management, 2015, 2, 367-382.	0.5	4
43	Impact of the 2009 <scp>AJCC</scp> staging guidelines for melanoma on the number of mitotic figures reported by dermatopathologists at one institution. Journal of Cutaneous Pathology, 2015, 42, 536-541.	1.3	5
44	5-Hydroxymethylcytosine expression in metastatic melanoma versus nodal nevus in sentinel lymph node biopsies. Modern Pathology, 2015, 28, 218-229.	5.5	41
45	Decrease of 5â€hydroxymethylcytosine in rat liver with subchronic exposure to genotoxic carcinogens riddelliine and aristolochic acid. Molecular Carcinogenesis, 2015, 54, 1503-1507.	2.7	7
46	Melanoma Cell Galectin-1 Ligands Functionally Correlate with Malignant Potential. Journal of Investigative Dermatology, 2015, 135, 1849-1862.	0.7	29
47	Targeting Nodal in Conjunction with Dacarbazine Induces Synergistic Anticancer Effects in Metastatic Melanoma. Molecular Cancer Research, 2015, 13, 670-680.	3.4	22
48	Targeted next-generation sequencing reveals high frequency of mutations in epigenetic regulators across treatment-naÃ¯ve patient melanomas. Clinical Epigenetics, 2015, 7, 59.	4.1	49
49	Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth. Cell, 2015, 162, 1242-1256.	28.9	507
50	Loss of the epigenetic mark, 5-Hydroxymethylcytosine, correlates with small cell/nevoid subpopulations and assists in microstaging of human melanoma. Oncotarget, 2015, 6, 37995-38004.	1.8	14
51	Merkel cell carcinoma expresses vasculogenic mimicry: demonstration in patients and experimental manipulation in xenografts. Laboratory Investigation, 2014, 94, 1092-1102.	3.7	17
52	Evaluation of stromal HGF immunoreactivity as a biomarker for melanoma response to RAF inhibitors. Modern Pathology, 2014, 27, 1193-1202.	5.5	18
53	Biomarker evaluation of face transplant rejection: association of donor T cells with target cell injury. Modern Pathology, 2014, 27, 788-799.	5.5	71
54	ABCB5 Maintains Melanoma-Initiating Cells through a Proinflammatory Cytokine Signaling Circuit. Cancer Research, 2014, 74, 4196-4207.	0.9	118

#	Article	IF	Citations
55	Autophagy Gene Atg16l1 Prevents Lethal T Cell Alloreactivity Mediated by Dendritic Cells. Immunity, 2014, 41, 579-591.	14.3	87
56	Loss of 5-hydroxymethylcytosine correlates with increasing morphologic dysplasia in melanocytic tumors. Modern Pathology, 2014, 27, 936-944.	5.5	46
57	Melanoma epigenetics: novel mechanisms, markers, and medicines. Laboratory Investigation, 2014, 94, 822-838.	3.7	69
58	ABCB5 is a limbal stem cell gene required for corneal development and repair. Nature, 2014, 511, 353-357.	27.8	217
59	Stem cells and targeted approaches to melanoma cure. Molecular Aspects of Medicine, 2014, 39, 33-49.	6.4	44
60	Melanoma Spheroid Formation Involves Laminin-Associated Vasculogenic Mimicry. American Journal of Pathology, 2014, 184, 71-78.	3.8	25
61	Keloids and Hypertrophic Scars. Plastic and Reconstructive Surgery - Global Open, 2013, 1, e25.	0.6	117
62	Diagnostic implications of loss of 5-hydroxymethylcytosine for melanoma. Expert Review of Dermatology, 2013, 8, 99-101.	0.3	5
63	Epigenetic and stem cell biomarkers in experimental melanoma metastases. FASEB Journal, 2013, 27, 53.6.	0.5	0
64	Inhibition of lysineâ€specific histone demethylase LSD1 suppresses melanoma growth. FASEB Journal, 2013, 27, 1088.15.	0.5	2
65	Expression of MDRâ€transporter, ABCB5, in Merkel cell carcinoma. FASEB Journal, 2013, 27, 1087.8.	0.5	0
66	IFNâ€gamma specifically targets melanoma stem cells and inhibits in vitro spherogenic growth. FASEB Journal, 2013, 27, 1087.11.	0.5	0
67	Floating cultured melanoma cells are a distinct subpopulation enriched for cancer stem cell biomarkers. FASEB Journal, 2013, 27, 1087.2.	0.5	0
68	Loss of 5-Hydroxymethylcytosine Is an Epigenetic Hallmark of Melanoma. Cell, 2012, 150, 1135-1146.	28.9	688
69	Histological Assessment of Cutaneous Acute Graft-Versus-Host Disease in a Preclinical Swine Model of Hematopoietic Cell Transplantation and Vascularized Skin Flap Tolerance. Blood, 2012, 120, 1894-1894.	1.4	0
70	Abrogation of Donor T Cell IL-21 Signaling Leads to Tissue-Specific Modulation of Immunity and Separation of Gvhd From GVL. Blood, 2010, 116, 729-729.	1.4	0
71	NOD2 Regulates Hematopoietic Cell Function During Graft-Versus-Host Disease.. Blood, 2009, 114, 2453-2453.	1.4	0
72	Depletion of Vascular Endothelial Progenitor Cells Inhibits Inflammation. Blood, 2008, 112, 694-694.	1.4	0

#	Article	IF	Citations
73	Target Cells in Graft-Versus-Host Disease: Implications for Cancer Therapy. Clinical Reviews in Allergy and Immunology, 2007, 33, 113-123.	6.5	5
74	An epithelial target site in experimental graft-versus-host disease and cytokine-mediated cytotoxicity is defined by cytokeratin 15 expression. Biology of Blood and Marrow Transplantation, 2003, 9, 559-570.	2.0	36
75	Capsule Dermatopathology: Clinicopathologic Types of Malignant Melanoma â€“ Relevance to Biologic Behavior and Diagnostic Surgical Approach. The Journal of Dermatologic Surgery and Oncology, 1985, 11, 674-682.	0.8	5
76	Capsule Dermatopathology: Origin of Malignant Epithelial Neoplasms of the Skin. The Journal of Dermatologic Surgery and Oncology, 1984, 10, 341-344.	0.8	0
77	Primary lymphoma of bone the relationship of morphologic diversity to clinical behavior. Cancer, 1982, 50, 1009-1014.	4.1	100